Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily ...
Is nearing full enrollment for its NEO100-01 Phase 2a trial, with top-line data readout anticipated in early 2026. The final patient cohort in its NEO212 Phase I trial is also on track for completion ...
News-Medical.Net on MSN
Scientists uncover 53 genetic clues that shape math ability beyond IQ
Researchers uncovered 53 genetic loci linked to quantitative ability, distinguishing it from general intelligence and ...
A driver who caused a crash that killed her and a friend while high on ecstasy was “not used to driving in this country”, an ...
Don't confuse biology with behavior. Here are five simple ways to help kids reset their brains and bodies after school.
NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) ('NeOnc” or the 'Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, ...
The Texas Tribune on MSN
Data centers are thirsty for Texas’ water, but state planners don’t know how much they will need
A wave of massive data centers is expanding across Texas, prompting warnings from experts who say the new water demands could ...
Queerty on MSN
Maxwell Poessnecker on lifting heavy weights, raising chickens & finding his athletic identity as a trans man
Growing up, Maxwell Poessnecker participated in every sport he could. But the fitness enthusiast never considered himself an ...
Phase 2 ASCEND trial of solengepras, a novel, non-dopaminergic GPR6 inhibitor, showed evidence of potential benefit in ...
Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.
NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback